KJ-101 / KisoJi Biotech - LARVOL DELTA

Pre-clinical development of a dopamine receptor 2, PD-1, and CD47 trispecific antibody for the treatment of solid tumors (AACR 2023) - "Conventional purification yields 99% purity and notably displays high stability under accelerated stability testing.In conclusion, the trispecific KJ-101 antibody has strong in vivo anti-tumor activity mediated via multiple mechanisms of action, is easily expressed and purified, and is very stable. Together, this data supports the clinical development of KJ-101 in advanced metastatic neuroendocrine cancer indications, including SCLC."

IO biomarker • Preclinical • Trispecific • Endocrine Cancer • Lung Cancer • Neuroendocrine Tumor • Oncology • Small Cell Lung Cancer • Solid Tumor • Triple Negative Breast Cancer • CD34 • DRD2 • PD-1 • SIRPA